Introduction {#Sec1}
============

The use of iodinated contrast media (CM) has increased over the past decades and is a well-known cause of acute renal failure, especially in patients with impaired renal function and/or in those with diabetes mellitus \[[@CR1]--[@CR3]\]. Iodinated contrast medium-induced nephropathy (CIN) is a potentially serious complication of diagnostic or interventional procedures leading to dialysis, prolonged hospitalization, increased morbidity and mortality \[[@CR4]\].

Iodinated CM are either ionic or nonionic and vary in their osmolality relative to plasma. It is now widely acknowledged that high-osmolality CM (ionic) are more nephrotoxic than low-osmolality contrast media (LOCM), ionic or nonionic, in at-risk patients \[[@CR5]\]. However, whether there are differences in safety among the various CM, particularly with regard to nephrotoxicity, remains controversial. Many clinical studies and meta-analyses have compared the safety of the various CM; however, depending on the patient population and study design, results are controversial \[[@CR6]--[@CR13]\].

CIN is generally characterised by an increase in serum creatinine of more than 25% or 0.5 mg/dl (44 μmol/l) over baseline, occurring within 3 days of CM administration. Serum creatinine is a relatively crude measure of glomerular filtration rate, and it has been suggested that creatinine clearance should be used to identify at-risk patients, as it provides better indication of renal function \[[@CR14], [@CR15]\].

The incidence of CIN is low (around 5%) in patients without risk factors, but is increased (up to 50%) in patients with multiple risk factors \[[@CR16]\]. These risk factors include contrast dose, contrast osmolality, previous CM injection and route of administration of CM \[[@CR17]\]. The risk of CIN is estimated to be more than twofold lower when administered intravenously rather than intra-arterially \[[@CR14], [@CR18]\].

Few clinical studies have compared the renal effects of intravenous administration of a low osmolar and an iso-osmolar contrast agent. There are very few studies of the effects in children in particular \[[@CR19], [@CR20]\].

Whether the use of an isotonic contrast agent confers any additional benefit in children compared with a low-osmolar agent is unclear. Therefore, the purpose of this randomized phase IV multicenter study was to compare the incidence of CIN in children undergoing enhanced multidetector computer tomography (MDCT) after intravenous administration of a low-osmolar (iobitridol) or an iso-osmolar (iodixanol) contrast agent.

Materials and methods {#Sec2}
=====================

Study conduct and patient enrollment conditions {#Sec3}
-----------------------------------------------

The study was approved by the Institutional Review Board of each participating center and performed according to good clinical practice standards. Informed written consent was obtained from each patient and/or patient's parents before any study-specific procedures were performed.

Children between 1 and 16 years of age with normal renal function (creatinine clearance \>60 ml/min/1.73 m^2^, calculated by the Schwartz's formula \[[@CR21]\]), scheduled to undergo a clinically indicated contrast-enhanced MDCT examination were considered eligible for inclusion. Patients were excluded from the trial in case of pregnancy or known hypersensitivity to iodine-containing compounds. Patients were also excluded if they had received any iodinated contrast agent within 7 days before the administration of the investigational product, if they were scheduled to receive an iodinated contrast agent within 72 h after administration of the investigational product, if they received any nephrotoxic medication (chemotherapeutic agents, diuretics or biguanide), or if they had any surgery planned within 72 h after the administration of the contrast agent.

After obtaining written informed consent and verifying all selection criteria, patients included in the study were then allocated an identification number corresponding to their chronological rank of inclusion. Patients were assigned randomly to intravenous administration of the LOCM iobitridol (695 mOsm/kg H~2~O) or the IOCM iodixanol (290 mOsm/kg H~2~O). LOCM are defined as CM with an osmolality two to three times that of normal human blood at an iodine concentration around 300 mg/ml. IOCM are defined as CM that are iso-osmolar to blood at an iodine concentration around 320 mg/ml. All groups and individuals associated with the study remained blinded to the type of contrast medium until the database was locked and the data analyzed. The randomization list was stratified by center. The MDCT images were assessed subjectively on-site by one experienced reader at each participating site. If needed, patients between 1 and 6 years received hydroxyzine for sedation (2 mg/kg body weight). Pre-procedure hydration was not implemented in this study.

Contrast medium administration {#Sec4}
------------------------------

To ensure blinding at the investigational sites, a third-party operator dispensed the drugs, managed the preparation, dispensation and accountability of the investigational agents, as per code assignment. The sole responsibility of all operators who dispensed the drugs was to preserve the blinding, and therefore they did not participate in any of the study assessments.

Contrast medium (iobitridol, Xenetix® 300, Guerbet Laboratories, Roissy, France or iodixanol, Visipaque® 270, GE Healthcare SA) was administered by intravenous injection according to a total volume depending on the patient's weight. All scans were performed following administration of 2 ml/kg body weight, maximum 100 ml, of contrast medium. The first part of the study applied a maximum volume of 50 ml.

Evaluation of primary and secondary endpoints {#Sec5}
---------------------------------------------

The primary endpoint was the relative change \[[@CR22]\] in creatinine clearance from 48 h before to 72 h after contrast medium administration using a noninferiority analysis.

The secondary endpoints were the incidence of CIN (defined as more than 25% reduction in creatinine clearance), global image quality on a 3-point scale (poor: low and inhomogeneous enhancement of target structures, moderate: little, but still homogeneous enhancement of target structures, good: adequate, almost completely homogeneous signal enhancement of target structures) and diagnosis efficacy on a 3-point scale (impossible: not providing enough information, difficult: not providing all the expected information, easy: providing the expected information). Moreover, the safety profile (vital signs and adverse events) of both contrast agents was also recorded. Any event from inclusion until the end of the 10-day follow-up period was collected and reported.

We evaluated the causality between the investigational product and /or concomitant therapy and the adverse event. The imputability of any reactions to the contrast agent was excluded if no causal relationship existed between the study drug and the event and an obvious alternative cause existed (e.g., the patient's underlying medical condition or concomitant therapy).

Statistical analysis {#Sec6}
--------------------

Assuming that the relative variation of the creatinine clearance from baseline is around 0.10 (10%) on average for both contrast agents with a 0.10 standard deviation, a sample of 128 patients was considered sufficient for 80% power and 2.5% type-1 error to ensure that if the difference between both products would not exceed −0.05 in disfavor of iobitridol, the noninferiority of iobitridol would be demonstrated over iodixanol. Assuming a 10% dropout, the sample size was extended to 142 patients to reach the main study objective.

Creatinine clearance was calculated in both groups before and after injection of contrast agents and the relative variation of these measures was computed and compared in each group. The noninferiority analysis on the primary endpoint was tested using the noncentral Student's *t*-test with a 2-sided type-1 error set at 0.05. The noninferiority of iobitridol over iodixanol was established if the observed difference between groups differed from the noninferiority clinical limit set at −0.05 in the study. This margin was considered by the study investigators as clinically sufficiently low to conclude a non-difference between the contrast agents.

Descriptive statistics were used for demography and baseline characteristics. The statistical test used for analyzing CIN incidence, image quality and diagnostic efficacy was the Wald Chi-2 test using a generalized linear model. The *P*-value for the main effect (difference between products) was adjusted on centers, mainly to take into account the stratification of the randomization by centre.

Statistical analyses were conducted using the software SAS version 9.1 (SAS Institute, Cary, N.C.).

The intent-to-treat (ITT) population refers to patients receiving at least one injection of contrast agent, and presenting with a valid creatinine clearance variation. The findings in this population were used for the primary and secondary criteria analyses. The per protocol (PP) population includes patients where there was no protocol deviation or violation. This population was also included in the primary and secondary criteria analyses. The safety population included all patients who received at least one dose of the study product and was used for the safety analyses.

Results {#Sec7}
=======

Patients {#Sec8}
--------

Between May 2006 and March 2009, 146 children with normal kidney function scheduled to undergo clinically indicated MDCT were recruited. One patient did not receive the product, hence, 145 children were randomized to receive iobitridol 300 (*n* = 74) or iodixanol (*n *= 71), and were all eligible for the safety analysis.

As shown in Table [1](#Tab1){ref-type="table"}, the two treatment groups were well-balanced with regard to demographic and baseline data. None of the patients had renal insufficiency. The most common indication was the "others" category, with the largest sub categories being liver transplant assessment, headache and Crohn disease. Table 1Demographic and baseline characteristics, indications for multidetector computer tomography (MDCT) and patient condition. *BMI* Body mass indexIobitridol 300 (*n* = 74)Iodixanol 270 (*n* = 71)Total (*n* = 145)Baseline characteristics Age (years) mean ±SD, (min--max)8.7 ±4.8 (1.0--16.0)8.1 ±4.7 (0.0--16.0)8.4 ±4.7 (0.0--16.0) Male43 ( 58.1 % )43 (60.6 %)86 (59.3 %) Female31 ( 41.9 % )28 (39.4 % )59 (40.7%) BMI (kg m^−2^) mean ±SD, (min--max)17.7 ±3.7 (12.7--33.6)17.4 ±3.2 (11.8--25.7)17.6 ±3.4 (11.8--33.6) Baseline serum creatinine (μmol/l) mean ±SD, (min--max)46.4 ±15.8 (17.9--84.0)43.6 ±17.1 (15.0--89.0)45.0 ±16.5 (15.0--89.0) Baseline creatinine clearance (ml min^−1^ 1.73 m^−2^) mean ±SD, (min--max)154.7 ±44.3 (70.8--315.6)157.9 ±44.4 (73.5--260.7)156.4 ±44.2 (70.8--315.6)Indications for MDCT examination (N, %)Congenital malformation Cardiac15 (20.3%)11 (15.5%)26 (17.9%) Vascular5 (6.8 %)4 (5.6 %)9 (6.2 %) Others3 (4.1 %)5 (7.0 %)8 (5.5 %)Tumors Abdomino-pelvic1 (1.4%)5 (7.0%)6 (4.1%) Cerebral1 (1.4 %)3 (4.2%)4 (2.8 %) Others6 (8.1 %)3 (4.2%)9 (6.2 %) Trauma6 (8.1%)4 (5.2 %)10 (6.9%) Other^a^41 (55.4%)42 (59.2%)83 (57.2%)Patient disposition Total number of randomized patients7471145 Safety population74 (100%)71 (100%)145 (100%) Intent-to-treat population62 (83.8% )66 (93.0%)128 (88.3%) Per protocol population29 (39.2%)39 (54.9%)68 (46.9%)^a^Mainly liver transplantation, headache and Crohn disease

Among the 146 children enrolled in the study, 18 were excluded from the ITT analysis, making 128 children eligible for the ITT population. The main reason for excluding children from ITT analysis was missing creatinine measurement.

From the ITT population, 68 children were free of major protocol deviations and were therefore eligible for the per-protocol analysis. The main reasons for excluding children from PP analysis were creatinine measurement out of time frame (48 h before injection or 72 ± 24 h after injection), contrast medium dose out of range (2 ml/kg ±10%) and code breaking.

Primary endpoint {#Sec9}
----------------

In the ITT population (*n* = 128), the mean difference (iobitridol−iodixanol) in creatinine clearance variation from baseline was −0.12% (*P* = 0.042), which was significantly different from the noninferiority margin (−0.05), demonstrating the noninferiority of iobitridol over iodixanol. The results were consistent in the per-protocol population (68 children), with a mean difference of 2.2% (*P* = 0.027; Table [2](#Tab2){ref-type="table"}). Table 2Increase in creatinine clearance at day  3 following contrast medium administration compared to baseline. *ITT* Intent-to-treat population, *PP* per protocol populationCreatinine clearance (ml min^−1^ 1.73 m^−2^)Iobitridol 300Iodixanol 270Difference (iobitridol-iodixanol) (90% confidence interval) *P*ITT*n* = 62*n* = 66−0.12% (−0.0481; 0.0456) *P* = 0.042Mean (%±SD)0.011 ±0.1970.019 ±0.220Min/max−0.387/0.953−0.584/0.769PP*n* = 29*n* = 392.2% (−0.0405; 0.0844) *P* = 0.027Mean (%±SD)0.039 ±0.2220.018 ±0.200Min/max−0.237/0.953−0.320/0.693

Secondary endpoints {#Sec10}
-------------------

### CIN incidence {#Sec11}

CIN was observed in 3/62 patients (4.8%) with iobitridol and 7/66 patients (10.6%) with iodixanol, with no statistically significant difference between groups in the ITT population (*P* = 0.72). Similar results were found in the PP population (*P* = 0.68) (Table [3](#Tab3){ref-type="table"}). Characteristics of these patients are detailed in Table [4](#Tab4){ref-type="table"}. Table 3Incidence of contrast medium-induced nephropathy (CIN) (creatinine clearance reduced \>25% compared to baseline)Iobitridol 300Iodixanol 270*P*^a^ITT*n* = 62*n* = 660.723 (4.8%)7 (10.6%)PP*n* = 29*n* = 390.680 (0%)4 (10.3%)^a^Wald Chi-2 test using a generalized linear model. The *P*-value for the main effect (difference between products) was adjusted on centersTable 4Characteristics of children with contrast medium-induced nephropathyPatientsGender/ age (years)BMI (kg m^−2^)Volume administered (mL)Relative variation in creatinine clearance (%)Indications for MDCTIobitridol\#1Female/1118.374-26Bile-duct atresia with secondary cirrhosis complication\#2Male/415.126-32Neck tumor\#3Male/216.726-39Kawasaki diseaseIodixanol\#4Female/1215.688-32Liver transplantation\#5Male/41632-40Chronic osteomyelitis\#6Female/717.250-29Cerebral tumor\#7Female/1214.350-58Cystic fibrosis\#8Female/213.820-28Retroperitoneal tumor\#9Male/116.624-29Pneumonia\#10Female/1622.970-26Pulmonary graft versus host reaction

### Image quality assessment {#Sec12}

The image quality rated "good" was similar in both groups: 52/62 patients (83.9%) with iobitridol 300 versus 59/66 patients (89.4%) with iodixanol 270, with no statistically significant difference between groups (*P* = 0.73) (Table [5](#Tab5){ref-type="table"}). Table 5Image quality and diagnostic efficacy assessmentsIobitridol 300 (*n* = 62)Iodixanol 270 (*n* = 66)*P*^a^Image quality Poor/moderate10 (16.1%)7 (10.6%)0.73 Good52 (83.9%)59 (89.4%)Diagnostic efficacy Impossible/difficult6 (9.7%)1 (1.5%)0.58 Easy56 (90.3%)65 (98.5%)^a^Wald Chi-2 test using a generalized linear model. The *P*-value for the main effect (difference between products) was adjusted on centres

Image quality was judged as "poor" or "moderate" in patients with high BMI, in those who did not receive a sufficient dose, and in the one case with extravasation, in the iobitridol group, when contrast administration had to be suspended.

### Diagnostic efficacy {#Sec13}

The diagnostic efficacy rated "easy" was similar in both groups: 56/62 patients (90.3%) with iobitridol 300 versus 65/66 patients (98.5%) with iodixanol 270, with no statistically significant difference between groups (*P* = 0.58) (Table [5](#Tab5){ref-type="table"}).

When the diagnostic efficacy was assessed as impossible or difficult, this was related mainly to patients with poor or moderate image quality.

### General safety {#Sec14}

The mean volume of contrast agent injected was 54.2 ml (10--100 ml). The mean amount of iodine administered was slightly higher in the iobitridol 300 group \[16.3 ±7.3 g (3.0--30.0)\] compared to the iodixanol 270 group \[14.6 ±7.0 g (3.24--27.0)\].

All patients were followed for 10 days after MDCT. A total of 16/74 patients (21.6%) with iobitridol 300 and 17/71 patients (23.9%) with iodixanol 270 experienced at least one adverse event. A total of 43 adverse events were observed: 20 (46.5%) with iobitridol 300 (including two pre-injection adverse events) and 23 (53.4%) with iodixanol 270. Most of these were of mild/moderate intensity. Relationship to the products was assumed for 9 (45%) adverse events (1 case of pruritis, 3 cases of rash, 1 case of extravasation and 4 cases of increased creatinine) with iobitridol 300 and 12 (52.1%) adverse events (1 case each of dermatitis, injection site warmth, pyrexia, rash and nausea, 5 cases of increased blood creatinine and 2 cases of vomiting) with iodixanol 270.

A total of nine serious adverse events were reported, five following iobitridol 300 and four following iodixanol 270. None of these was considered related to the products.

Discussion {#Sec15}
==========

This double-blind, randomized, controlled study performed in children with normal renal function showed that iobitridol 300 was noninferior to iodixanol 270 in terms of relative variation of the creatinine clearance despite a higher iodine load in the iobitridol group.

Many studies have demonstrated that high-osmolar contrast media are more nephrotoxic than new generation, low and iso-osmolar alternatives \[[@CR3], [@CR23], [@CR24]\], as also noted in the guidelines from the European Society of Urogenital Radiology \[[@CR25]\]. Two of the most widely used new contrast media, iodixanol (a nonionic, iso-osmolar dimer) and iobitridol (a nonionic low-osmolar monomer), have consistently been found adequately safe in adults, both in intravenous administration to high-risk patients \[[@CR26]\]. However, Chalmers and Jackson found that iodixanol was less nephrotoxic than iohexol (another nonionic low-osmolar monomer), when administered to patients with renal impairment \[[@CR27]\]. This superior safety of iodixanol compared to iohexol was also suggested in the NEPHRIC study \[[@CR13]\].

In our study including children with normal renal function, iobitridol 300, a low-osmolar contrast agent (695 mOsm/Kg), appeared to be associated with a lower CIN incidence rate (4.8%) compared to iodixanol 270 (10.6%), an iso-osmolar agent (290 mOsm/kg). To our knowledge, this is the first study performed in children with normal renal function; therefore, as there is no available data regarding the CIN incidence on this kind of population, no comparison can be made.

To evaluate whether iodixanol provides a general benefit over other low-osmolar agents in patients with impaired renal function, a number of prospective clinical studies have been conducted recently. The results of these studies showed that the overall benefit of iodixanol over other low-osmolar agents cannot be demonstrated. Briguori and colleagues \[[@CR10]\] reported that CIN rates were not significantly different when patients with chronic renal insufficiency were randomized to iodixanol or iobitridol for angiography procedures. In the RECOVER study, iodixanol was compared to the ionic dimer ioxaglate \[[@CR11]\]. In this latter study, a significant reduction in the CIN incidence was shown with iodixanol, but only when the two endpoints, serum creatinine increases ≥ 0.5 mg/dL or 25% from baseline, were combined. Another recent study, ICON, \[[@CR28]\] failed to demonstrate a benefit with iodixanol over ioxaglate in patients with impaired renal function who underwent cardiac angiography. Barrett and colleagues \[[@CR12]\] also reported low incidence of CIN in patients with chronic kidney disease randomly assigned to receive iodixanol or iopamidol for contrast-enhanced CT (2.6% versus 0%, respectively, *P* = 0.2). The CARE study \[[@CR29]\], another and larger study (414 patients), also failed to demonstrate a benefit with iodixanol over iopamidol in renally impaired cardiac angiography patients. Rates of CIN were comparable after using the two agents (12.4% versus 9.4%, respectively, *P* = 0.44). In the ACTIVE trial (148 patients), Thomsen and colleagues \[[@CR30]\] concluded that the CIN incidence was significantly higher after intravenous administration of iodixanol 320 than iomeprol 400, with an overall rate of CIN in all study groups of 3.4%. Kuhn and colleagues \[[@CR14]\] in the PREDICT study (248 patients) concluded that the overall CIN rate was 5.2% with iodixanol 320 and iopamidol 370 in patients with both renal impairment and diabetes mellitus who underwent CE-MDCT. Rudnick et al. in the VALOR trial \[[@CR31]\] including 299 patients showed that the CIN incidence was 21.8% with iodixanol and 23.8% with ioversol (*P* = 0.78), and suggested that the nephrotoxicity associated with iodixanol was not significantly different from that observed with the low-osmolar contrast agent. In a recent meta-analysis by Heinrich et al. \[[@CR32]\], a reduction in nephrotoxicity was seen only when iodixanol was compared with iohexol, but no benefit was seen when this IOCM was compared with other LOCM. The results of Alexopoulos et al. \[[@CR33]\] showed that no differences in contrast-induced acute kidney injury incidence were apparent among patients receiving nonionic iso-osmolar iodixanol and nonionic low-osmolar contrast agents.

As described above, most of the published reports studied adult patients with pre-existing renal insufficiency and the criteria which identified cases of CIN were not uniform.

Also, the results of our study suggest that differences in CIN incidence cannot be explained solely by differences in contrast media osmolality \[[@CR34]\]. The mechanism of contrast-induced nephropathy is multifactorial and unclear. As described in some studies, factors other than osmolality (such as viscosity, temperature, hydrophilicity) may also contribute to the toxic effect of contrast products \[[@CR35]--[@CR37]\], and perhaps both osmolality and viscosity may also contribute to nephrotoxicity.

The efficacy and safety of iobitridol have been assessed recently in a double-blind, randomized study \[[@CR38]\] and a German postmarketing surveillance study involving more than 160,000 patients \[[@CR39]\], showing in both studies a diagnostic value and a good safety profile of iobitridol. Regarding the efficacy results in our study, the diagnostic value of MDCT performed in children was shown. The image quality rated "good" was high and similar in both groups, with no statistically significant difference. Although the incidence of patients rated "poor/moderate" was slightly higher with iobitridol 300 (16.1%) than that observed with iodixanol 270 (10.6%), this difference can be explained by patients with a high BMI and/or those not receiving a sufficient dose. The diagnostic efficacy rated "easy" was also similar in both groups, with no statistically significant difference.

Finally, the similar and good safety profile of both products was confirmed, and the low incidence of CIN observed in our study suggests that prophylaxis is not required in children when using iobitridol 300 and iodixanol 270.

Conclusion {#Sec16}
==========

This trial suggests that, despite the greater iodine dose, there was no statistically significant difference in the rate of CIN between iobitridol 300 and iodixanol 270 in children with normal renal function. The osmolality of the contrast agent alone probably does not account for the differences in the incidence of CIN. While previous reports have suggested osmolality as a factor in the pathogenesis of CIN at high osmolalities (\>1,000 mOsm/kg), our results suggest that osmolality in the range of 300 to approximately 700 is not nephrotoxic. Also, for contrast media within this range of osmolality, other characteristics such as viscosity or direct molecular toxicity may play a greater role in the development of CIN. Future prospective clinical trials comparing low and iso-osmolar, as well as low- and high-viscosity CM in high-risk pediatric patients would be of great interest to explore the role of osmolality and viscosity in CIN.
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